Paper Details

  1. Home
  2. Paper Details

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.

Author: , AurivilliusMagnus, BarkerPeter, BleeckerEugene R, BusseWilliam W, FergusonGary T, FitzGeraldJ Mark, GilmartinGeoffrey, GoldmanMitchell, KornStephanie, LommatzschMarek, NairParameswaran, OhtaKen, SprouleStephanie, WerkströmViktoria

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study assessed the efficacy and safety of benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as an add-on therapy for patients with severe, uncontrolled asthma and elevated blood eosinophil counts.
Paper Details　
Original Abstract of the Article :
Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We aimed to assess the efficacy and safety of benralizumab as add-on therapy for patients with severe, uncontrolled asthma and elevat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(16)31322-8

データ提供：米国国立医学図書館（NLM）

Benralizumab: A Wind of Change for Severe Asthma

This research explores the efficacy and safety of benralizumab, a monoclonal antibody that targets the interleukin-5 receptor, for treating severe, uncontrolled, eosinophilic asthma. The authors conducted a randomized, double-blind, placebo-controlled phase 3 trial to evaluate benralizumab's effectiveness as add-on therapy. Their findings demonstrate that benralizumab significantly improved lung function and reduced asthma exacerbations in patients with severe, uncontrolled asthma and elevated blood eosinophil counts.

Benralizumab: A Beacon of Hope in the Desert of Asthma

This study provides encouraging results for benralizumab, a new treatment option for severe, uncontrolled, eosinophilic asthma. The authors found that benralizumab significantly improved lung function and reduced asthma exacerbations compared to placebo. This suggests that benralizumab may be a valuable tool for managing this challenging condition.

Navigating the Desert of Asthma Management

This study highlights the potential benefits of benralizumab for patients with severe, uncontrolled asthma. Benralizumab offers a promising new treatment option, particularly for those with elevated blood eosinophil counts. However, the study also emphasizes the importance of individualized care, considering factors like the patient's specific needs and disease characteristics.

Dr.Camel's Conclusion

This study offers a breath of fresh air for patients with severe, uncontrolled asthma. Benralizumab shows promise as a new treatment option, potentially easing the burden of this debilitating condition. Like a gentle breeze in the desert, benralizumab may bring hope and relief to many patients.
Date :
  1. Date Completed 2017-04-10
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

27609406

DOI: Digital Object Identifier

10.1016/S0140-6736(16)31322-8

Related Literature

Article Analysis
・Effects of benralizumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.